(−) -C75

• Description :

  () -C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM[1][2][3]. C75 is a potent CPT1A activator[5].

• UNSPSC :

  12352005

• Target :

  Fatty Acid Synthase (FASN)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/c75-1.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CCCCCCCC[C@@H]([C@@H](C1=C)C(O)=O)OC1=O

• Molecular Formula :

  C14H22O4

• Molecular Weight :

  254.32

• References & Citations :

  [1]Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1;105 (3) :550-560.|[2]Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.|[3]Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+) -C75 is a strong anorectic drug; (-) -C75 has antitumor activity. Chirality. 2013 May;25 (5) :281-7.|[4]Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100 (10) :5628-33.|[5]Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99 (14) :9498-502.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1234694-22-4]